Cardinal Health gets RBC Buy, $276 target on Nuclear Medicine
RBC Capital Markets initiates Cardinal Health with a buy rating and a $276 price target, citing the company’s Nuclear Medicine business and its expected profit contribution.
CAH RBC Capital Markets initiated Club name Cardinal Health with a buy rating and price target of $276.
That's more optimistic than our $265 price target, which we increased last week after the drug distributor issued rosy profit guidance for fiscal 2027.
RBC likes Cardinal's Nuclear Medicine business, which makes and distributes radiopharmaceuticals used in Imaging tests.
They expect Nuclear to drive a lot of profits going forward. - per Cramer Investing Club Newsletter